Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
Biohaven initiated first-in-human Phase 1 dosing of BHV-8100, an oral, brain-penetrant PKM2 modulator targeting metabolic restoration and immunomodulation. Preclinical data using the Bexorg BrainEx platform showed 3-fold improvement in glucose utilization in human brains, with preferential metabolic rescue in Alzheimer's disease donor brains versus controls.
Key figures
- Drug Name
- BHV-8100
- Phase Of Trial
- Phase 1
- Alzheimer patients us
- 6.5 million
- Alzheimer annual cost us
- $300 billion
- Alzheimer patients global
- 55 million
- Retinal disease market 2030
- $15 billion
- Glucose utilization improvement
- 3-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.